The global clinical next-generation sequencing (NGS) data analysis market enjoys a valuation of US$ 2.3 Billion in 2023, and it is further projected to expand at a CAGR of 17.4% over the forecasted years. According to a recent study by Future Market Insights, NGS data analysis & sequencing services are leading the market with a share of about 41.8% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2023 | US$ 2.3 Billion |
| Market Value 2033 | US$ 13.1 Billion |
| CAGR 2023 to 2033 | 17.4% |
| Market Share of Top 5 Countries | 66.0% |
| Key Market Players | Agilent Technologies, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Eurofins Scientific, BGI Group, Qiagen, Roche Diagnostics, DNA Star, Inc., Bio-Rad Laboratories, Inc., Congenica Ltd., Theragen Etex Inc., PerkinElmer, Inc., Partek Inc., Oxford Nanopore Technologies PLC., Pacific Biosciences of California, Inc., Golden Helix, Inc., and BioDatomics. |
In order to determine DNA/RNA sequences for the complete genome or to examine a particular region of interest connected to diseases or biological processes, a breakthrough method called next-generation sequencing is being developed. The market for clinical next-generation sequencing data analysis has expanded because of the demand for comprehensive information on genomic sequences.
The nucleotide sequence of entire genomes or specific portions of DNA or RNA can be ascertained using NGS data analysis tools. Sequence alignment, alignment visualisation, gene prediction, and variation analysis tools are a few of the NGS data analysis tools.
With its extremely high throughput, scalability and speed, next-generation sequencing (NGS) is a massively parallel sequencing technology. The sequencers utilised in the sequencing process are known as next-generation sequencing platforms. The NGS platforms contribute to the vast scale delivery of exceptionally high data quality and accuracy.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 11.9% between 2014 and 2022, owing to the rising prevalence of various chronic diseases.
The global market holds around 39.2% share of the overall global DNA sequencing market with a value of around US$ 5.8 Billion, in 2022.
One of the key factors propelling growth of the market in the coming years is the increasing number of life sciences companies. With the expansion of the life sciences industry, numerous small and medium-sized companies are entering the market with novel product offerings and more complex technology to set themselves apart from competitors. Companies conduct extensive research in order to provide novel products.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 13.1 billion during the year 2033.
Technological advances in genomic-based bioinformatics tools are providing many opportunities for market growth. A sizable amount of genetic data is now accessible on web-based bioinformatics platforms because of recent advancements in bioinformatics research and technologies.
Research analysts or data scientists can now compare and assess the quality of their sequencing run, assess in-line control validation, assign sequences to known regions, and characterise other sequences that reflect certain immune receptor clones.
One can infer information about unique immune response traits, their associated current illness scenario, and the consequences of therapeutic antigen presentation by understanding the abundance of particular clones and how they fluctuate in relation to treatment response and disease progression.
Performing tests on relatively tiny samples allows for efficient analysis from easily available material without the need for extra sampling, which is another benefit of genomic-based analyses.
For instance, Illumina released a BaseSpace Informatics Suite in 2014 that enables a lab to follow genetic tests even if it has no genomic computing infrastructure of its own. The suite's extensive software library makes it simple to carry out ordinary data analysis of sequences.
Principal Consultant
In undeveloped countries, there is less access to modern infrastructure. Therefore, the only alternative for using these technologies to carry out immune repertoire sequencing experiments is outsourcing. Additionally, some outsourcing companies in poor countries are known for offering inferior services.
To be precise, these companies do not actually offer the sequencing service. Instead, they serve as local service providers for companies with operations abroad. They submit samples to companies in other countries for sequencing, and then they get the results. Poor service delivery occurs during the transit and sequence process time due to a number of variables, including inappropriate sample handling, transportation issues, and lengthy wait periods.
Overall, the process is quite costly, takes a long time, and often takes several months to provide the desired outcomes. Therefore, low quality of outsourcing services is likely to limit the overall market growth.
The USA dominates the North American region with a total market share of around 89.1% in 2022 and is expected to continue to experience the same growth throughout the forecast period. The regional dominance is attributed to increasing cancer cases in the region. For instance, according to American Cancer Society, in 2022, 1.9 million new cancer cases were diagnosed and around 609,360-cancer related deaths in the United States were estimated.
Various FDA approvals and rapid technological developments have helped in the growth of this region.
Germany held a market share of around 32.1% in 2022 in the European clinical next-generation sequencing (NGS) data analysis market, owing to increasing collaboration, acquisition, and mergers by the market players in the region. For instance, in April 2022, Illumina and Hannover Medical School signed a contract to evaluate the use of rapid whole-genome sequencing in critically ill kids who are thought to have a hereditary or uncommon condition.
Also, the region is heavily focused on research and developments in the pharmaceutical industry, biotechnological industry, and novel technological developments, which is boosting the market for clinical next-generation sequencing (NGS) data analysis.
China holds a market share of 56.3%, with a market value of US$ 107.7 Million in the East Asia clinical next-generation sequencing (NGS) data analysis market in 2022. Increasing prevalence of autism a disorder that causes substantial distress is the main factor stimulating the regional market. For instance, according to NHC Study Team. Prevalence of Autism Spectrum Disorder in China: A Nationwide Multi-center Population-based Study among Children Aged 6 to 12 Years. Neurosci Bull. 2020, out of 142,086 around 363 children were confirmed having autism spectrum disorder.
Disruptive variations in the genome's protein-coding regions can be found with next-generation sequencing (NGS). These NGS techniques changed the search for the ASD gene in conjunction with big cohorts and new statistical techniques. In order to understand the neurobiological effects of altering these ASD-associated genes, functional genetic data, such as gene expression, is greatly benefited from the use of NGS techniques.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
NGS data analysis & sequencing services are expected to give high growth at a CAGR of 15.2% between 2023 and 2033. This is because services for NGS data analysis are readily available and reasonably priced. For companies with inadequate infrastructure, this service offers management and interpretation support.
For instance, ArrayGen Technologies provides a broad range of NGS data processing services in the fields of cancer genomics, crop biotechnology, personalised medicine, and disease association research. A comparable selection of NGS data analysis services is offered by ThermoFisher Scientific. The segment growth is attributable to the readily accessible, reasonably priced NGS data analysis services.
Sequencing by synthesis (SBS) is widely adopted with the market share of 42.7% in the global market in 2022. DNA polymerases and dNTPs are employed to replicate (or synthesise) the strand that has to be sequenced in the sequencing by synthesis technique.
De novo sequencing, long-insert paired-end reads for fast sequence assembly, and other applications are provided by SBS technology as well as to short-insert coupled reads for high-resolution genomic studies. Combining short inserts with long reads improves the ability to fully characterise any genome. The segment increase is attributable to SBS's affirmative technology elements.
Medical research in global clinical next-generation sequencing data analysis market is widely used, holding a market share of 39.6% in the global market in 2022. This segment is predicted to increase significantly because of the use of NGS for the study of tumour heterogeneity, the identification of new genes connected to cancer, and the finding of changes related to carcinogenesis.
The Genomic Medicine Service of the National Health Service in the United Kingdom has adopted a sequencing-based method for the clinical investigation of cancer with an unknown cause and the evaluation of potential treatments. Increase in such sequencing-based approaches for various research is anticipated to boost the segment growth.
Academic institutes & research centres hold a market share of 37.7% during the year 2022. Increasing adoption of NGS software platforms the factors attributed for segment growth. Several academic and research organisations now use more NGS software platforms for their projects requiring data interpretation because of falling NGS technology costs.
A further factor that is expected to promote income production in this sector is the gradual increase in the number of qualified employees handling software and computational tools in research institutions. Several institutions provide on-site bioinformatics training programmes and courses with the goal of improving knowledge of various sequencing data analysis options.
Major manufacturers are striving to increase the market reach of both their key products and the solutions they offer to consumers. For instance, today's top manufacturers often offer specialised solutions based on the needs of different end users. Due to the high level of competition in the market, many top competitors are heavily concentrating on various market consolidation operations like merger, acquisition, supply distribution partnerships, and the introduction of new products.
Instances of important developmental strategies used among market participants in the clinical next-generation sequencing (NGS) data analysis market are presented below:
Similarly, the team at Future Market Insights has tracked recent developments related to companies within the clinical next-generation sequencing (NGS) data analysis space. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2014 to 2022 |
| Forecast Data | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, The United Kingdom, Germany, Italy, Russia, Spain, France, Benelux, Nordics Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Solution and Services, Technology, Application, End User, and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global clinical next-generation sequencing (NGS) data analysis market value was US$ 2.3 billion in 2022.
In 2022, the revenue generated from sales to academic institutes and research centre was 37.7% of the total.
The China market was valued at US$ 107.7 million that is 56.3% of the global market in 2022.
NGS data analysis & sequencing services segment is forecasted to grow at 15.2% CAGR through 2033.
Sequencing by synthesis (SBS) technology is widely adopted and had 42.7% market share in 2022.
1. Executive Summary | Clinical Next-Generation Sequencing (NGS) Data Analysis Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply–Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 3.3. Regional Trends 4. Key Success Factors 4.1. NGS Data Analysis Tools Adoption and Usage Analysis 4.2. Key Promotional Strategies by Manufacturers 4.3. Regulatory Landscape 4.4. PESTLE Analysis 4.5. Porter’s Analysis 4.6. Reimbursement Scenario 5. Market Background 5.1. Macro–Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure 5.1.3. Global DNA Sequencing Market Outlook 5.2. Forecast Factors – Relevance & Impact 5.2.1. Technological Advancement in NGS Sequencing Tools 5.2.2. Growing Innovations and Wide Industry Scope 5.2.3. Significant Developments in the Research and Biotechnology Space 5.2.4. Investments by Various Local Players 5.2.5. Adoption Rate of NGS Sequencing Services 5.2.6. Key Players’ Historic Growth 5.2.7. Growing Healthcare Expenditure 5.2.8. Regulatory Scenario 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity 6. COVID–19 Crisis – Impact Assessment 6.1. Impact of COVID–19: An Overview 6.2. COVID–19 and Impact Analysis 6.2.1. By Solution and Services 6.2.2. By Technology 6.2.3. By Application 6.2.4. By End User 6.2.5. By Region 6.3. 2022 Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2014 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2014 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y–o–Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Solution and Services 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Solution and Services, 2014 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Solution and Services, 2023 to 2033 8.3.1. NGS Data Analysis Tools 8.3.1.1. Sequence Alignment Tools 8.3.1.2. Alignment Visualization Tools 8.3.1.3. Gene Prediction Tools 8.3.1.4. Variant Analysis Tools 8.3.1.5. Others 8.3.2. Platforms 8.3.2.1. Next–Generation Sequencing (NGS) Platforms 8.3.2.2. Clinical Informatics Platforms 8.3.2.3. Others 8.3.3. NGS Data Analysis & Sequencing Services 8.3.3.1. Whole–Genome Sequencing (WGS) 8.3.3.2. Whole Exome Sequencing (WES) 8.3.3.3. Comprehensive genomic profiling (CGP) 8.3.3.4. Custom Panels 8.3.3.5. RNA Sequencing 8.3.3.6. Other Sequencing Services 8.3.4. NGS Storage, Management & Cloud Computing Platform 8.4. Market Attractiveness Analysis By Solution and Services 9. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Technology 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By Technology, 2014 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Technology, 2023 to 2033 9.3.1. Sequencing by Synthesis (SBS) 9.3.2. Nanopore Sequencing 9.3.3. Single–Molecule Real–Time (SMRT) Sequencing 9.3.4. Others 9.4. Market Attractiveness Analysis By Technology 10. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) By Application, 2014 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033 10.3.1. Diagnostics 10.3.2. Drug Discovery & Designing 10.3.3. Medical Research 10.3.4. Others 10.4. Market Attractiveness Analysis By Application 11. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) By End User, 2014 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 11.3.1. Hospitals & Clinics 11.3.2. Academic Institutes & Research Centres 11.3.3. Biotechnology Companies 11.3.4. Life Science Technology Vendors 11.3.5. Others 11.4. Market Attractiveness Analysis By End User 12. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Region, 2014 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2014 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. USA 13.3.1.2. Canada 13.3.2. By Solution and Services 13.3.3. By Technology 13.3.4. By Application 13.3.5. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Solution and Services 13.4.3. By Technology 13.4.4. By Application 13.4.5. By End User 13.5. Market Trends 13.6. Key Market Participants – Intensity Mapping 13.7. Drivers and Restraints – Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. USA Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Solution and Services 13.8.1.2.2. By Technology 13.8.1.2.3. By Application 13.8.1.2.4. By End User 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Solution and Services 13.8.2.2.2. By Technology 13.8.2.2.3. By Application 13.8.2.2.4. By End User 14. Latin America Market Analysis 2014 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Solution and Services 14.3.3. By Technology 14.3.4. By Application 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Solution and Services 14.4.3. By Technology 14.4.4. By Application 14.4.5. By End User 14.5. Market Trends 14.6. Key Market Participants – Intensity Mapping 14.7. Drivers and Restraints – Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Solution and Services 14.8.1.2.2. By Technology 14.8.1.2.3. By Application 14.8.1.2.4. By End User 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Solution and Services 14.8.2.2.2. By Technology 14.8.2.2.3. By Application 14.8.2.2.4. By End User 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Solution and Services 14.8.3.2.2. By Technology 14.8.3.2.3. By Application 14.8.3.2.4. By End User 15. Europe Market Analysis 2014 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. United Kingdom 15.3.1.2. Germany 15.3.1.3. France 15.3.1.4. Italy 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Solution and Services 15.3.3. By Technology 15.3.4. By Application 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Solution and Services 15.4.3. By Technology 15.4.4. By Application 15.4.5. By End User 15.5. Key Market Participants – Intensity Mapping 15.6. Drivers and Restraints – Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. U.K. Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Solution and Services 15.7.1.2.2. By Technology 15.7.1.2.3. By Application 15.7.1.2.4. By End User 15.7.2. Germany Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Solution and Services 15.7.2.2.2. By Technology 15.7.2.2.3. By Application 15.7.2.2.4. By End User 15.7.3. France Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Solution and Services 15.7.3.2.2. By Technology 15.7.3.2.3. By Application 15.7.3.2.4. By End User 15.7.4. Italy Market Analysis 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Solution and Services 15.7.4.2.2. By Technology 15.7.4.2.3. By Application 15.7.4.2.4. By End User 15.7.5. Spain Market Analysis 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Solution and Services 15.7.5.2.2. By Technology 15.7.5.2.3. By Application 15.7.5.2.4. By End User 15.7.6. BENELUX Market Analysis 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Solution and Services 15.7.6.2.2. By Technology 15.7.6.2.3. By Application 15.7.6.2.4. By End User 15.7.7. Nordic Countries Market Analysis 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Solution and Services 15.7.7.2.2. By Technology 15.7.7.2.3. By Application 15.7.7.2.4. By End User 15.7.8. Russia Market Analysis 15.7.8.1. Introduction 15.7.8.2. Market Analysis and Forecast by Market Taxonomy 15.7.8.2.1. By Solution and Services 15.7.8.2.2. By Technology 15.7.8.2.3. By Application 15.7.8.2.4. By End User 16. East Asia Market Analysis 2014 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Solution and Services 16.3.3. By Technology 16.3.4. By Application 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Solution and Services 16.4.3. By Technology 16.4.4. By Application 16.4.5. By End User 16.5. Key Market Participants – Intensity Mapping 16.6. Drivers and Restraints – Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. China Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Solution and Services 16.7.1.2.2. By Technology 16.7.1.2.3. By Application 16.7.1.2.4. By End User 16.7.2. Japan Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Solution and Services 16.7.2.2.2. By Technology 16.7.2.2.3. By Application 16.7.2.2.4. By End User 16.7.3. South Korea Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Solution and Services 16.7.3.2.2. By Technology 16.7.3.2.3. By Application 16.7.3.2.4. By End User 17. South Asia Market Analysis 2014 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Malaysia 17.3.1.3. Thailand 17.3.1.4. Indonesia 17.3.1.5. Rest of South Asia 17.3.2. By Solution and Services 17.3.3. By Technology 17.3.4. By Application 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Solution and Services 17.4.3. By Technology 17.4.4. By Application 17.4.5. By End User 17.5. Key Market Participants – Intensity Mapping 17.6. Drivers and Restraints – Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. India Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Solution and Services 17.7.1.2.2. By Technology 17.7.1.2.3. By Application 17.7.1.2.4. By End User 17.7.2. Malaysia Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Solution and Services 17.7.2.2.2. By Technology 17.7.2.2.3. By Application 17.7.2.2.4. By End User 17.7.3. Thailand Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Solution and Services 17.7.3.2.2. By Technology 17.7.3.2.3. By Application 17.7.3.2.4. By End User 17.7.4. Indonesia Market Analysis 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Solution and Services 17.7.4.2.2. By Technology 17.7.4.2.3. By Application 17.7.4.2.4. By End User 18. Oceania Market 2014 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Solution and Services 18.3.3. By Technology 18.3.4. By Application 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Solution and Services 18.4.3. By Technology 18.4.4. By Application 18.4.5. By End User 18.5. Key Market Participants – Intensity Mapping 18.6. Drivers and Restraints – Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. Australia Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Solution and Services 18.7.1.2.2. By Technology 18.7.1.2.3. By Application 18.7.1.2.4. By End User 18.7.2. New Zealand Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Solution and Services 18.7.2.2.2. By Technology 18.7.2.2.3. By Application 18.7.2.2.4. By End User 19. Middle East and Africa (MEA) Market Analysis 2014 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. Rest of Middle East and Africa 19.3.2. By Solution and Services 19.3.3. By Technology 19.3.4. By Application 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Solution and Services 19.4.3. By Technology 19.4.4. By Application 19.4.5. By End User 19.5. Key Market Participants – Intensity Mapping 19.6. Drivers and Restraints – Impact Analysis 19.7. Country Level Analysis & Forecast 19.7.1. GCC Countries Market Analysis 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Solution and Services 19.7.1.2.2. By Technology 19.7.1.2.3. By Application 19.7.1.2.4. By End User 19.7.2. Türkiye Market Analysis 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Solution and Services 19.7.2.2.2. By Technology 19.7.2.2.3. By Application 19.7.2.2.4. By End User 19.7.3. North Africa Market Analysis 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Solution and Services 19.7.3.2.2. By Technology 19.7.3.2.3. By Application 19.7.3.2.4. By End User 19.7.4. South Africa Market Analysis 19.7.4.1. Introduction 19.7.4.2. Market Analysis and Forecast by Market Taxonomy 19.7.4.2.1. By Solution and Services 19.7.4.2.2. By Technology 19.7.4.2.3. By Application 19.7.4.2.4. By End User 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players (%) 20.3. Market Presence Analysis 20.3.1. By Regional Footprint of Players 20.3.2. Product Footprint of Players 20.3.3. Channel Footprint of Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Agilent Technologies, Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Key Financials 21.3.1.4. SWOT Analysis 21.3.1.5. Key Developments 21.3.1.6. Sales Footprint 21.3.1.7. Strategy Overview 21.3.2. Illumina, Inc. 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Key Financials 21.3.2.4. SWOT Analysis 21.3.2.5. Key Developments 21.3.2.6. Sales Footprint 21.3.2.7. Strategy Overview 21.3.3. Thermo Fisher Scientific, Inc. 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Key Financials 21.3.3.4. SWOT Analysis 21.3.3.5. Key Developments 21.3.3.6. Sales Footprint 21.3.3.7. Strategy Overview 21.3.4. Eurofins Scientific 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Key Financials 21.3.4.4. SWOT Analysis 21.3.4.5. Key Developments 21.3.4.6. Sales Footprint 21.3.4.7. Strategy Overview 21.3.5. BGI Group 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Key Financials 21.3.5.4. SWOT Analysis 21.3.5.5. Key Developments 21.3.5.6. Sales Footprint 21.3.5.7. Strategy Overview 21.3.6. Qiagen 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Key Financials 21.3.6.4. SWOT Analysis 21.3.6.5. Key Developments 21.3.6.6. Sales Footprint 21.3.6.7. Strategy Overview 21.3.7. Roche Diagnostics 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Key Financials 21.3.7.4. SWOT Analysis 21.3.7.5. Key Developments 21.3.7.6. Sales Footprint 21.3.7.7. Strategy Overview 21.3.8. DNAStar, Inc. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Key Financials 21.3.8.4. SWOT Analysis 21.3.8.5. Key Developments 21.3.8.6. Sales Footprint 21.3.8.7. Strategy Overview 21.3.9. Bio–Rad Laboratories, Inc. 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Key Financials 21.3.9.4. SWOT Analysis 21.3.9.5. Key Developments 21.3.9.6. Sales Footprint 21.3.9.7. Strategy Overview 21.3.10. Congenica Ltd. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Key Financials 21.3.10.4. SWOT Analysis 21.3.10.5. Key Developments 21.3.10.6. Sales Footprint 21.3.10.7. Strategy Overview 21.3.11. Theragen Etex Inc. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Key Financials 21.3.11.4. SWOT Analysis 21.3.11.5. Key Developments 21.3.11.6. Sales Footprint 21.3.11.7. Strategy Overview 21.3.12. PerkinElmer, Inc. 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Key Financials 21.3.12.4. SWOT Analysis 21.3.12.5. Key Developments 21.3.12.6. Sales Footprint 21.3.12.7. Strategy Overview 21.3.13. Partek Inc. 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Key Financials 21.3.13.4. SWOT Analysis 21.3.13.5. Key Developments 21.3.13.6. Sales Footprint 21.3.13.7. Strategy Overview 21.3.14. Oxford Nanopore Technologies PLC. 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Key Financials 21.3.14.4. SWOT Analysis 21.3.14.5. Key Developments 21.3.14.6. Sales Footprint 21.3.14.7. Strategy Overview 21.3.15. Pacific Biosciences of California, Inc. 21.3.15.1. Overview 21.3.15.2. Product Portfolio 21.3.15.3. Key Financials 21.3.15.4. SWOT Analysis 21.3.15.5. Key Developments 21.3.15.6. Sales Footprint 21.3.15.7. Strategy Overview 21.3.16. Golden Helix, Inc. 21.3.16.1. Overview 21.3.16.2. Product Portfolio 21.3.16.3. Key Financials 21.3.16.4. SWOT Analysis 21.3.16.5. Key Developments 21.3.16.6. Sales Footprint 21.3.16.7. Strategy Overview 21.3.17. BioDatomics 21.3.17.1. Overview 21.3.17.2. Product Portfolio 21.3.17.3. Key Financials 21.3.17.4. SWOT Analysis 21.3.17.5. Key Developments 21.3.17.6. Sales Footprint 21.3.17.7. Strategy Overview 21.3.18. PierianDx 21.3.18.1. Overview 21.3.18.2. Product Portfolio 21.3.18.3. Key Financials 21.3.18.4. SWOT Analysis 21.3.18.5. Key Developments 21.3.18.6. Sales Footprint 21.3.18.7. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Clinical Next-Generation Sequencing (NGS) Data Analysis Market
